It can also be calculated by dividing the company’s Market Cap by the Net Profit. There’s big news for Guardant Health (GH 1.35%) shareholders today — but disappointing news also. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. In 2022, the United States accounted for 94% of revenue, and other markets the remaining 6%.
- Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment.
- The Motley Fool has positions in and recommends Guardant Health.
- 15 analysts have issued 12-month price targets for Guardant Health’s shares.
- 52 week low is the lowest price of a stock in the past 52 weeks, or one year.
- Nowak covers the Healthcare sector, focusing on stocks such as CareDx, Celcuity, and QuidelOrtho.
In a report released on October 10, Scotiabank also assigned a Buy rating to the stock with a $47.00 price target. Guardant Health issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $545.00 million-$550.00 million, compared to the consensus revenue estimate of $541.39 million. According to 14 analysts, the average rating for GH stock is “Strong Buy.” The 12-month stock price forecast is $54.79, which is an increase of 102.70% from the latest price.
(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.
Guardant Health to Host Investor Day on September 7, 2023
There’s no better time to master new investing skills—get 50% off all IBD Online Courses. When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Guardant Health (GH) stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from … These companies’ growth stories still have plenty of exciting chapters ahead. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
The consensus among Wall Street research analysts is that investors should “buy” GH shares. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.
- Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
- Analysts have a consensus estimate of $137.16 million for the company’s revenue for the quarter, with a low and high estimate of $130.3 million and $143.1 million respectively.
- The GF Value represents the current intrinsic value of a stock derived from our exclusive method.
- View analysts price targets for GH or view top-rated stocks among Wall Street analysts.
- Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat’s FREE daily newsletter.
It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA. Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven velocity trade days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that GH is a 100% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
Benzinga’s Top Ratings Upgrades, Downgrades For September 27, 2023
You must click the activation link in order to complete your subscription. Rich Smith has no position trade99 review in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health.
It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Guardant Health Inc 52 week low is $20.67 as of October 14, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Guardant Health Inc 52 week high is $54.47 as of October 14, 2023. When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
Last month, Chudova Darya, the CTO of GH bought 4,500.00 shares for a total of $39,600.00. In the market, a comparison of Guardant Health Inc (GH) and its peers suggest the former has performed considerably weaker. Data shows GH’s intraday price has changed -5.89% in last session and -46.67% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.62% and -0.51% respectively in the last trading. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
Blood Tests for Cancer Look More Competitive. What It Means for Illumina’s Antitrust Fight.
The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. The precision oncology leader benefited from a pair of positive analyst notes this week. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
Analysts have a consensus estimate of $137.16 million for the company’s revenue for the quarter, with a low and high estimate of $130.3 million and $143.1 million respectively. The average forecast suggests up to a 16.40% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2023 to grow to $548.92 million, representing a 22.10% jump on that reported in the last financial year. Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $48.56 average price target, a 71.35% upside from current levels.
The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS).
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
/PRNewswire/ — USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in… You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.